報價延遲最少15分鐘:2026/06/01 16:33 EDT
盤後時段
|
||||
|
4.64 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.04/0.59
|
|
企業價值
160.45M
|
| 資產負債 |
|
每股賬面淨值
-0.38
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.23M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
